A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma
Status:
Recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
This is a phase II, open-label, single center study, aiming to investigate safety and
efficacy of anlotinib in treatment of recurrent high-grade glioma.